Ropinirole - extended-release tablets | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

ER Parkinson regimen is not the IR RLS schedule

The official ER source has a once-daily dialysis starting regimen. Its maximum does not make IR and ER starting doses or indications interchangeable.

Before applying: Confirm exact release formulation and indication. The failed REQUIP XL mirror has not been recovered by adding an official generic label.

Also check: ER Parkinson regimen is not the IR RLS schedule

Official source

Ropinirole - extended-release tablets

Product / population: Ropinirole - extended-release tablets; selected renal passages, not a complete prescribing monograph.
Renal measure: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.

The RX REQUIP XL destination failed retrieval in this R pass. This official supplement is not counted as recovered RX content.

Renal dosing, restrictions and evidence limits

For Parkinson disease, CrCl 30-50 mL/min needs no adjustment. With regular hemodialysis, start extended-release ropinirole at 2 mg once daily and titrate to response and tolerability; maximum 18 mg/day. No supplemental postdialysis dose is required. Severe impairment below 30 without regular dialysis has not been studied. These once-daily tablets are not the immediate-release RLS regimen. Do not transfer the IR starting frequency or treat an ER tablet as interchangeable without the label-specific conversion instructions.

Source revision: Prescribing information revised November 2025. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=307411be-1c4e-44f7-b94d-737a3384c107

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Ropinirole - extended-release tablets

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Ropinirole - extended-release tablets; selected renal passages, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

ER Parkinson regimen is not the IR RLS schedule

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

scope and safety

ER Parkinson regimen is not the IR RLS schedule

The official ER source has a once-daily dialysis starting regimen. Its maximum does not make IR and ER starting doses or indications interchangeable.

How to use this: Confirm exact release formulation and indication. The failed REQUIP XL mirror has not been recovered by adding an official generic label.

Ropinirole - extended-release tablets Ropinirole - immediate-release tablets

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

Ropinirole - extended-release tablets

Ropinirole - extended-release tablets; selected renal passages, not a complete prescribing monograph.

Method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Ropinirole - extended-release tablets

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=307411be-1c4e-44f7-b94d-737a3384c107

Exact product and population

Ropinirole - extended-release tablets; selected renal passages, not a complete prescribing monograph.

RDM52-SCOPE-ropinirole-extended-release · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Ropinirole - extended-release tablets

Open original reference

Open / share this exact local source

DailyMed / Elite Laboratories, Inc. · Ropinirole - extended-release tablets; selected renal passages, not a complete prescribing monograph.

Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Source date: Prescribing information revised November 2025.
Retrieved: 2026-09-09

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM52-official-ropinirole-extended-release-19b82add10-C1 · Source locator: Dosage and Administration: general dosing and renal impairment; Indications and Usage.

Source-specific limits

The RX REQUIP XL destination failed retrieval in this R pass. This official supplement is not counted as recovered RX content.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=307411be-1c4e-44f7-b94d-737a3384c107
Retrieved: 2026-09-09
Exact label title: ROPINIROLE - ropinirole tablet, extended release
DailyMed Set ID: 307411be-1c4e-44f7-b94d-737a3384c107
Labeler: Elite Laboratories, Inc.
Label revision: Prescribing information revised November 2025.
FDA application: ANDA217862
Renal-function method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
Source date/version: Prescribing information revised November 2025.
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: b1fb304ecda4a208e92dc948b7b744af87f4cc2ec8b807f50c78ab449e002424

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=307411be-1c4e-44f7-b94d-737a3384c107
Source retrieval: 2026-09-09. This is not the source publication or label revision date.
Original source type: source summary
Local text SHA-256: fe0914462563818dc5cbeac7cf40c421b664d5cba5a10956a3f8e1746bed114f
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report